#3 - UnitedHealth Group (NYSE:UNH)
If you’re looking for a no-brainer stock to own, you should consider UnitedHealth Group Inc. (NYSE: UNH). The company is one of the nation’s largest health insurers. Specifically, the company is the leading provider of family health plans offered through the Affordable Care Act (ACA) health marketplaces.
This includes Medicare Advantage plans, which are expected to show strong growth in coming years. Plus, the company may benefit from consumers moving away from Humana Inc. (NYSE: HUM) and CVS Health Co. (NYSE: CVS) plans.
Admittedly, $1,000 won’t buy you much of UNH stock which trades for $606.04 as of this writing. However, the stock has delivered a total return of over 189% in the last five years. That’s a reminder of the stock’s dividend, which has increased for 15 consecutive years. Future stock price growth would get a boost if Kamala Harris were to win the presidency in November. However, Medicare spending will continue to increase no matter which party is in office.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Read More - Current Price
- $500.13
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $626.84 (25.3% Upside)
